Solid Tumor Protocols / Clinical Studies

For information on these and other studies, referring physicians may e-mail protocolinfo@stjude.org or call toll free physician referral line, 1-888-226-4343. If you are not a physician, please e-mail info@stjude.org for information on St. Jude studies.

 

Therapeutic Trial for Newly Diagnosed Patients with Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

For: Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

 
 

A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) with and without Natural Killer Cells to Chemotherapy in Children and Adolescents with Recurrent/Refractory Neuroblastoma

For: Recurrent / refractory neuroblastoma

 
 

International Pediatric Adrenocortical Tumor Registry Data Collection

For: adrenocortical carcinoma

 
 

Neuroblastoma Protocol 2012: Therapy for Children with Advanced Stage High-Risk Neuroblastoma

For: Neuroblastoma

 
 

A Phase I Trial of RAD001 (Everolimus) and AVASTIN (Bevacizumab) in Children with Recurrent Solid Tumors

For: Refractory/relapsed solid tumor or brain tumor

 
 

A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children with Relapsed or Refractory Solid Tumors or Lymphomas

For: Relapsed or refractory solid tumors or lymphomas

 
 

Risk Adapted Focal Proton Beam Radiation and/or Surgery in Participants with Low and Intermediate Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

For: Rhabdomyosarcoma (Low-risk and intermediate-risk)

 
 

Image Guided Radiotherapy for the Treatment of Musculoskeletal Tumors: A Phase II Prospective Evaluation of Radiation-related Treatment Effects

For: Ewing sarcoma; rhabdomyosarcoma; primitive neuroectodermal tumors (PNET) of the musculoskeletal system; soft tissue sarcomas; other bone sarcomas; chordoma

 
 

A Phase I trial of the humanized anti-GD2 antibody (hu14.18K322A) in children and adolescents with neuroblastoma, osteosarcoma and melanoma

For: Neuroblastoma, osteosarcoma and melanoma

 
 

Protocol for the Study and Treatment of Participants with Intraocular Retinoblastoma

For: Retinoblastoma

 

Non St. Jude Protocols

 

A Phase I Study of XL184 (Cabozantinib, IND# 116059) In Children and Adolescents with Recurrent or Refractory Solid Tumors, Including CNS Tumors (ADVL1211)

For: Recurrent or refractory solid tumors, including CNS tumors

 
 

A Phase I Study of Crizotinib (IND#105573) In Combination with Conventional Chemotherapy For Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

For: Relapsed or refractory solid tumors or anaplastic large cell lymphoma

 
 

A Phase I Study of the TEM-1 Antibody, MORAb-004 (IND# 103821) in Children with Relapsed or Refractory Solid Tumors (ADVL1213)

For: Relapsed or refractory solid tumors

 
 

A Phase I/II Study of PF-02341066, An Oral Small Molecule Inhibitor Of Anaplastic Lymphoma Kinase (ALK) And C-Met, In Children With Relapsed/Refractory Solid Tumors And Anaplastic Large Cell Lymphoma

For: Relapses/refractory solid tumors and anaplastic large cell lymphoma

 
 

Phase I/II a, 2-Part, Multi-Cancer, Single-Arm, Open-Label Study to determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 12 Months to < 18 Years with Advance BRAF V600-Mutation Positive Solid Tumors

For: Solid tumors, giomas, hystiosytosis

 
 

A Phase I, Open-Label, Dose Escalation Study of LDK378 in Pediatric Patients with Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

For: Refractory or progressive malignancies

 
 

A Phase 2 Study of Ipilimumab in Children and adolescents (12 to < 18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma

For: Previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma

 
 

An Open-label, Multicenter, Single-arm, Phase I Dose-escalation with Efficacy Tail Extension study of R05185426 in Pediatric Patients with Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600

For: melanoma

 
 

Treatment for Patients with Bilateral, Multicentric, or Bilaterally- Predisposed Unilateral Wilms Tumor

For: Wilms tumor

 
 

A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma

For: Extra-occular retinoblastoma

 
 

A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung

For: recurrent osteosarcoma